azacitidine has been researched along with Neoplasms, Pleural in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aoe, K; Date, H; Fujimoto, N; Kimura, K; Kishimoto, T; Kubo, T; Otani, H; Pass, HI; Sano, Y; Soh, J; Suehisa, H; Toyooka, S; Tsukuda, K; Yamamoto, H | 1 |
| Amatori, S; Bagaloni, I; Catalano, A; Donati, B; Fanelli, M; Lazzarini, R; Papalini, F; Pelicci, PG; Procopio, A; Rippo, MR | 1 |
| Amatori, S; Bagaloni, I; Fanelli, M; Viti, D | 1 |
| Blanquart, C; Boutin, B; Fonteneau, JF; Grégoire, M; Gueugnon, F; Guillot, F; Leclercq, S; Padieu, M; Pouliquen, D; Rogel, A | 1 |
| Chen, GA; Figg, WD; Fischette, MR; Hancox, A; Hong, JA; Kunst, TF; Li, X; Murgo, AJ; Nguyen, DM; Pishchik, V; Schrump, DS; Steinberg, SM; Zhao, M | 1 |
| Antman, KH; Cirrincione, C; Citron, ML; Corson, JM; Green, MR; Harmon, DC; Herndon, JE; Suzuki, Y; Yogelzang, NJ | 1 |
| Aisner, J; Carey, R; Corson, JM; Green, MR; Harmon, DC; Herndon, JE; Samuels, BL; Suzuki, Y; Vogelzang, NJ | 1 |
| Dhingra, HM; Hong, WK; Murphy, WK; Raber, MN; Winn, RJ | 1 |
4 trial(s) available for azacitidine and Neoplasms, Pleural
| Article | Year |
|---|---|
Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura.
Topics: Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Decitabine; DNA Modification Methylases; Esophageal Neoplasms; Female; Gene Expression Regulation, Neoplastic; Genes, p16; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Membrane Proteins; Mesothelioma; Middle Aged; Neoplasm Proteins; Pleural Neoplasms; Transcriptional Activation | 2006 |
Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Arrhythmias, Cardiac; Azacitidine; Chest Pain; Female; Humans; Male; Mesothelioma; Middle Aged; Pleural Neoplasms | 1997 |
Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chest Pain; Cisplatin; Female; Humans; Leukopenia; Male; Mesothelioma; Middle Aged; Pleural Neoplasms; Prognosis; Survival Analysis | 1998 |
Phase II trial of 5,6-dihydro-5-azacytidine in pleural malignant mesothelioma.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Drug Evaluation; Female; Humans; Male; Mesothelioma; Middle Aged; Pleural Neoplasms | 1991 |
4 other study(ies) available for azacitidine and Neoplasms, Pleural
| Article | Year |
|---|---|
The aberrant promoter methylation of BMP3b and BMP6 in malignant pleural mesotheliomas.
Topics: Azacitidine; Bone Morphogenetic Protein 6; Cell Line, Tumor; Decitabine; DNA Methylation; Enzyme Inhibitors; Gene Expression; Growth Differentiation Factor 10; Humans; Japan; Mesothelioma; Pleural Neoplasms; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; United States | 2008 |
Decitabine, differently from DNMT1 silencing, exerts its antiproliferative activity through p21 upregulation in malignant pleural mesothelioma (MPM) cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Cycle; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Gene Silencing; Humans; Neoplasms, Mesothelial; Pleural Neoplasms; Up-Regulation | 2009 |
Premature senescence induced by DNA demethylating agent (Decitabine) as therapeutic option for malignant pleural mesothelioma.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cellular Senescence; Decitabine; DNA Methylation; Humans; Mesothelioma; Pleural Neoplasms | 2011 |
A 5-aza-2'-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Modification Methylases; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Membrane Proteins; Mesothelioma; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Pleural Neoplasms; T-Lymphocytes, Cytotoxic; Valproic Acid; Vorinostat | 2011 |